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Most recent report of results to date:
1. Introduction.  The objective of our research program was to determine whether novel
receptors  can  be  induced  in  solid  cancers  as  a  target  for  therapy  with  radiolabeled
unmodified peptides that bind to the receptors.  The hypothesis was that induction of a high
number of receptors on the surface of these cancer cells would result in an increased uptake
of the radiolabeled monomeric peptides as compared to published results with radiolabeled
antibodies or peptides to naturally expressed antigens or receptors, and therefore a better
therapeutic outcome.  The following is a summary of published results.
2. Induction of receptors  in vivo.  To evaluate the ability to induce receptor expression in
vivo,  a  replication-incompetent  adenovirus  (Ad)  encoding  the  gene  for  hSSTr2  under
control  of  the  cytomegalovirus  promoter  (AdCMVhSSTr2)  was injected  i.p. to  induce
hSSTr2 expression on SK-OV-3.ip1  tumors  growing in the peritoneum in nude  mice.
Tumor localization of  111In-DTPA-D-Phe1-octreotide 4 h after i.p. injection was equal to
60.4% ID/g of the radiolabeled peptide.  Other studies investigated the localization of 111In-
DTPA-D-Phe1-octreotide to s.c. A-427 non-small cell lung tumors injected intratumorally
(i.t.) with AdCMVhSSTr2.  The region of interest (ROI) analysis after gamma camera
imaging showed the tumor uptake of 111In-DTPA-D-Phe(1)-octreotide to be 2.8% ID/g 48 h
after injection and 3.1% ID/g at 96 h.  Gamma camera imaging was used to detect hSSTr2
expression in  s.c. A-427 tumors infected with AdCMVhSSTr2 using a  99mTc- or  188Re-
labeled somatostatin analogue P829.  Independent confirmation of hSSTr2 expression was
demonstrated by immunohistochemical analysis.
A novel 99mTc-labeled peptide (P2045) binds with high affinity to hSSTr2 and has favorable
in vivo biodistribution.  We evaluated this peptide in mice bearing SK-OV-3.ip1 tumors in
the peritoneum.  Tumor uptake of 99mTc-P2045 at 48 h after i.v. injection averaged 2.2 ±
0.3% ID/g for mice injected  i.p. with AdCMVhSSTr2 (1x109 pfu).  We also evaluated
99mTc-P2045 in mice bearing s.c. A-427 tumors injected i.t. with AdCMVhSSTr2 or with a
control  Ad.   The  images  showed  radioactive  uptake  in  the  tumors  injected  with
AdCMVhSSTr2 but background uptake in tumors injected with control Ad.
Further studies have been reported using a bicistronic Ad vector encoding hSSTr2 and
thymidine kinase (TK) in the same mouse tumor model.  The A-427 tumors were injected
i.t. with the bicistronic vector (AdCMVhSSTr2TK) and the animals imaged for hSSTr2
expression with 99mTc-P2045 and TK with 131I-FIAU.  The biodistribution results showed
the uptake of  99mTc-labeled P2045 and 131I-labeled FIAU for AdCMVhSSTr2TK-injected
tumors was 11.1% and 1.6% ID/g, respectively.
A separate therapy study was conducted with nude mice bearing naturally SSTR-positive
AR42J rat pancreatic tumors.  High tumor retention of 188Re-P2045 was observed.  Results
of a therapy study with 4 treatments over 2 weeks were previously presented.  There was a
clear relationship between tumor response and dose of 188Re-P2045.
3. Therapy  studies  with  the  single  gene  vector  AdCMVhSSTr2  and  90Y-SMT  487.
Another somatostatin analogue that has been used for therapy is  90Y-DOTA-D- Phe(1)-
Tyr3-octreotide  (90Y-SMT 487).   Nude  mice  were  inoculated  s.c. with  A-427  cells.
Twenty-four  days  later  the  mice  were  administered  1  x  109 pfu  AdCMVhSSTr2
intratumorally (Day 0).  Mice that received 2 i.t. injections of AdCMVhSSTr2 and 4 doses
of 400 µCi or 500 µCi 90Y-SMT 487 had median tumor quadrupling times of 40 and 44
days, respectively.  The log-rank test revealed a statistically significant difference in time to
tumor quadrupling between the AdCMVhSSTr2 + 90Y-SMT 487 treatment groups and the
control groups (p<0.02).
4. Therapy studies  with the bicistronic vector AdCMVhSSTr2CD and  90Y-SMT 487.
We constructed and evaluated bicistronic Ad vectors encoding for hSSTr2 and the CD
enzyme.  The CD converts the non-toxic prodrug 5-FC to the cytotoxic and radiosensitizing
drug 5-FU.  We investigated imaging of gene transfer in athymic nude mice bearing s.c. A-
427 tumors injected with 1x109 pfu AdCMVhSSTr2 or AdCMVhSSTr2CDRGD.  After 2
days, 99mTc-P2045 was i.v. injected and gamma camera imaging demonstrated localization
in the tumors.
Therapy studies were initiated with AdCMVhSSTr2CD and 90Y-SMT 487 in combination
with 5-FC.  Tumor inhibition results showed that both 90Y-SMT 487 and 90Y-SMT 487 in
combination with 5-FC slowed tumor growth.   Importantly,  the combination treatment
produced a greater tumor growth inhibition than the 90Y-SMT 487 treatment alone and the
levels of toxicity (weight loss) were modest.  However, as with the 90Y-SMT 487 treatment
alone, the tumors eventually regrew at an exponential rate.  Therefore, further modification
of this therapeutic regimen was necessary.
5. Therapy with the bicistronic vector AdCMVhSSTr2CD,  90Y-SMT 487, and external
beam radiation.  The rationale behind the use of 60Co with our therapeutic approach is that
external beam radiation is used in the treatment of many cancers and it can simulate the
higher radiation dose delivered to tumor when a better radiolabeled peptide is used.  Tumor
inhibition results were extremely encouraging as they show that the combination of  90Y-
SMT 487 + 5-FC + 3 Gy resulted in tumor regressions.  All combination therapies had at
least two complete regressions with most being recurrence-free.  The triple therapy groups
had the greatest mean tumor growth suppression over all treatment groups.
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